IN8bio, Inc. (INAB)
Largest Insider Buys in Sector
INAB Stock Price History Chart
INAB Stock Performance
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. …
Insider Activity of IN8bio, Inc.
Over the last 12 months, insiders at IN8bio, Inc. have bought $0 and sold $0 worth of IN8bio, Inc. stock.
On average, over the past 5 years, insiders at IN8bio, Inc. have bought $1.44M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $2,375 was made by Graff Jeremy R. (director) on 2023‑09‑13.
List of Insider Buy and Sell Transactions, IN8bio, Inc.
| 2023-09-13 | director | 2,500 0.0077% | $0.95 | $2,375 | +10.52% | |||
| 2023-08-25 | Chief Financial Officer | 1,000 0.0032% | $1.03 | $1,030 | +0.97% | |||
| 2023-08-24 | President and CEO | 23,800 0.0719% | $1.05 | $24,990 | +1.96% | |||
| 2022-12-12 | director | 75,001 0.359% | $2.48 | $185,912 | -44.94% | |||
| 2022-12-12 | director | 75,001 0.359% | $2.48 | $185,912 | -44.94% | |||
| 2022-09-28 | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | ||||
| 2022-09-28 | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | ||||
| 2022-08-26 | 31,805 0.1513% | $2.02 | $64,232 | -5.10% | ||||
| 2022-08-17 | 38,035 0.1712% | $1.93 | $73,408 | -5.30% | ||||
| 2022-08-17 | 38,035 0.1712% | $1.93 | $73,408 | -5.30% | ||||
| 2022-08-16 | 789,473 3.713% | $1.90 | $1.5M | +1.07% | ||||
| 2022-08-16 | President, CEO and CFO | 26,315 0.1238% | $1.90 | $49,999 | +1.07% | |||
| 2022-08-16 | 206,575 0.9715% | $1.90 | $392,493 | +1.07% | ||||
| 2022-08-16 | 206,575 0.9715% | $1.90 | $392,493 | +1.07% | ||||
| 2022-08-16 | 105,263 0.4951% | $1.90 | $200,000 | +1.07% | ||||
| 2022-08-16 | EVP and CSO | 526 0.0025% | $1.90 | $999 | +1.07% | |||
| 2022-08-16 | 26,315 0.1238% | $1.90 | $49,999 | +1.07% | ||||
| 2022-08-16 | 526 0.0025% | $1.90 | $999 | +1.07% | ||||
| 2022-08-16 | Chief Operating Officer | 5,263 0.0248% | $1.90 | $10,000 | +1.07% | |||
| 2022-08-16 | Chief Financial Officer | 5,263 0.0248% | $1.90 | $10,000 | +1.07% |
Insider Historical Profitability
| Transcend Partners Opportunity Fund LLC | 4111958 5.673% | $0.24 | 1 | 0 | +1.07% | |
| Fletcher Aaron G.L. | director | 3727597 5.1427% | $0.24 | 2 | 0 | <0.0001% |
| Kreis Leslie W. | director | 3727597 5.1427% | $0.24 | 2 | 0 | <0.0001% |
| Cavu Advisors, LLC | 3651528 5.0378% | $0.24 | 3 | 0 | <0.0001% | |
| BIOS Advisors GP, LLC | 3612569 4.984% | $0.24 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Aigh Capital Management Llc | $3.39M | 6.52 | 2.87M | -29.85% | -$1.44M | 1.94 | |
| The Vanguard Group | $1.68M | 3.23 | 1.42M | +241.71% | +$1.19M | <0.0001 | |
| Ensign Peak Advisors Inc | $1.32M | 2.53 | 1.12M | 0% | +$0 | <0.01 | |
| 683 Capital Management Llc | $725,410.00 | 1.39 | 614,754 | 0% | +$0 | 0.08 | |
| Sigma Planning Corp | $607,794.00 | 1.17 | 515,080 | +289.53% | +$451,762.70 | 0.02 |